Articles tagged "Heart transplant patients"

2016 American Transplant Congress
A New Diagnostic Score for Microvascular Inflammation in Antibody-Mediated Rejection in Heart Transplantation.
M. Racapé,¹ A. Loupy,² R. Guillemain,¹ A. François,³ P. Rouvier,⁴ C. Toquet,⁵ X. Jouven,¹ J. Venner,⁶ L. Hidalgo,⁶ J. Reeve,⁶ P. Bruneval,¹ J. Duong Van Huyen,² P. Halloran.²
¹European Georges Pompidou Hospital, Paris, France; ²Necker Hospital, Paris, France; ³Rouen University Hospital, Rouen, France; ⁴La Pitié Salpêtrière Hospital, Paris, France; ⁵Laennec Hospital, Nantes, France; ⁶University of Alberta, Edmonton, Canada.
BackgroundThe ISHLT working formulation defines Intravascular Activated Mononuclear Cells (IAMC) as one of the histopathologic features of antibody-mediated rejection (ABMR) in heart transplantation. However, no…
2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
A. Aliabadi,¹ J. Goekler,¹ O. Salameh,¹ T. Haberl,¹ B. Steinlechner,² P. Opfermann,² A. Kaider,¹ K. Uyanik-Uenal,¹ G. Laufer,¹ A. Zuckermann.¹
¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Cardiothoracic and Vascular Anaesthisiology, Medical University of Vienna, Vienna, Austria.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…
2016 American Transplant Congress
Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).
M. Bories,¹ S. Varnous,² C. Lefaucheur,³ P. Rouvier,² R. Guillemain,¹ P. Bruneval,¹ J. Duong Van Huyen,⁴ A. Loupy.⁴
¹European Georges Pompidou Hospital, Paris, France; ²La Pitié Salpêtrière Hospital, Paris, France; ³Saint-Louis Hospital, Paris, France; ⁴Necker Hospital, Paris, France.
Introduction The role of circulating DSA in addition to traditional cardiovascular risk factors, in the development of accelerated CAV have not been demonstrated. We investigated…
2016 American Transplant Congress
Anti-HLA Antibody Composition and Outcomes in Pediatric Heart Transplant Recipients with a Positive Cross-Match.
P. Jindra,¹ S. Nicholas,² J. Chappelle,¹ T. Humlicek,² K. Hosek,² J. Heinle,² S. Denfield,² A. Jeewa,² R. Kerman,¹ W. Dreyer.²
¹Surgery Immune Evaluation Lab, Baylor College of Medicine, Houston, TX; ²Pediatrics, Baylor College of Medicine, Houston, TX.
Purpose: Utilization of positive (+) cross-match (XM) hearts is tempting when shortages of pediatric donor hearts exist, especially for patients with high pre-transplant panel reactive…
2016 American Transplant Congress
The Quilty Effect in Pediatric Heart Transplant Recipients.
A. Joong,¹ M. Richmond,¹ K. Stack,² R. Rodriguez,¹ J. McAllister,² W. Zuckerman,¹ T. Lee,¹ S. Law,¹ L. Addonizio.¹
¹Pediatric Cardiology, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.
Purpose: The Quilty effect is defined as the presence of a nodular endocardial infiltrate of lymphocytes in an endomyocardial biopsy (EMB), and has been described…
2016 American Transplant Congress
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
M. Bakir, N. Jackson, E. Chang, D. Henriquez-Ticas, C.-H. Tseng, T. Khuu, J. Zhang, E. Reed, M. Deng, M. Cadeiras.
Cardiology, University of California-Los Angeles, Los Angeles, CA.
Purpose: The presence of circulating HLA antibodies which is termed allosensitization among heart transplant (HTx) candidates are associated with poorer posttransplant outcomes including increased morbidity…
2016 American Transplant Congress
Solid Phase Assay Demonstrates High Rates of Allosensitization in Pediatric Heart Recipients.
W. Zuckerman,¹ B. Feingold,² A. Zeevi,² C. Bentlejewski,² L. Addonizio,¹ E. Blume,³ C. Canter,⁴ A. Dipchand,⁵ D. Hsu,⁶ R. Shaddy,⁷ W. Mahle,⁸ K. Much,⁹ B. Armstrong,⁹ D. Ikle,⁹ H. Diop,¹⁰ J. Odim,¹⁰ S. Webber.¹¹
¹Columbia Univ., NYC; ²Univ. of Pittsburgh, Pittsburgh; ³Boston Children's Hospital, Boston; ⁴Washington Univ., St. Louis; ⁵Sick Kids, Toronto, Canada; ⁶Children's Hospital, Montefiore, NYC; ⁷Children's Hospital of Philadelphia, Philadelphia; ⁸CHOA, Atlanta; ⁹Rho, Chapel Hill; ¹⁰NIAID/NIH, Bethesda; ¹¹Vanderbilt Univ., Nashville.
Allosensitization is a risk factor for rejection, vasculopathy and graft loss. CTOTC-04 is a prospective study assessing the impact of sensitization on a composite of…
2016 American Transplant Congress
Impact of Donor Specific Antibodies on Cardiac Allograft Vasculopathy.
A. Vu,¹ A. Althouse,² A. Zeevi,³ J. Teuteberg,² M. Shullo.²
¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Pathology Department, University of Pittsburgh, Pittsburgh, PA.
Purpose: Cardiac allograft vasculopathy (CAV) is a significant complication after cardiac transplantation (CTX). The presence of donor specific antibodies (DSA) has been associated with an…
2016 American Transplant Congress
A Risk Quantification Score for Heart Transplants: A Heart Donor Risk Index.
A. Israni,^1,2 D. Zaun,¹ J. Snyder,¹ N. Salkowski,¹ H. Xiong,¹ B. Kasiske,^1,2 M. Colvin,^1,3 M. Colvin.^1,3
¹Scientific Registry of Transplant Recipients, Minneapolis; ²Hennepin County Medical Center, Univ of MN, Minneapolis; ³Univ of Michigan, Ann Arbor.
Background: To better risk stratify heart transplants, we developed a continuous heart donor risk index (HDRI) based on heart donors to quantify heart allograft failure.Methods:…
2016 American Transplant Congress
Relationship Between Changes in Brain Natriuretic Peptide Levels and Cardiac Allograft Rejection Early After Heart Transplantation.
J. Dann,¹ K. Deininger,¹ D. Reinhold,¹ R. Page II,¹ A. Ambardekar,¹ J. Lindenfeld,² C. Aquilante.¹
¹University of Colorado, Aurora, CO; ²Vanderbilt University, Nashville, TN.
Endomyocardial biopsies (EMBs) are routinely used to detect cardiac allograft rejection after heart transplantation (HTx), but they are invasive and costly. Serial changes in brain…